Provides gamma and electron beam irradiation sterilization services. Offers ethylene oxide (EO) processing for sterilization. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 6% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $1.9B. In times of high interest rates, a gap like that can squeeze a company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
Clearly below the class average.
This grade is a blend: the profit side is strong, the sales tempo slow.
Clearly above the class average — a step short of the very top.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
The stock trades 33% below its peak. The market has trimmed its expectations for the company.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
The company’s market value is 67 times its annual profit. Even a small disappointment could hit the price hard.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 24/100.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 47/100.
On our five-subject report card, SHC sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: SHC is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.